EGE
MCID: ESN005
MIFTS: 55

Eosinophilic Gastroenteritis (EGE)

Categories: Gastrointestinal diseases, Immune diseases, Rare diseases

Aliases & Classifications for Eosinophilic Gastroenteritis

MalaCards integrated aliases for Eosinophilic Gastroenteritis:

Name: Eosinophilic Gastroenteritis 12 73 20 58 54 15 70
Eosinophilic Gastroenterocolitis 20 58
Eosinophilic Enteritis 20 58
Ege 20 58
Eosinophilic Gastroenteropathy 20
Gastroenteritis, Eosinophilic 73
Eosinophilic Esophagitis 20
Eosinophilic Enteropathy 70
Eosinophilic Gastritis 20

Characteristics:

Orphanet epidemiological data:

58
eosinophilic gastroenteritis
Inheritance: Not applicable; Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Disease Ontology 12 DOID:4031
ICD9CM 34 558.41
NCIt 50 C35330
SNOMED-CT 67 359804008
MESH via Orphanet 45 C535952
ICD10 via Orphanet 33 K52.8
UMLS via Orphanet 71 C1262481 C2062326
Orphanet 58 ORPHA2070
UMLS 70 C1262481 C2062326

Summaries for Eosinophilic Gastroenteritis

GARD : 20 Eosinophilic gastroenteritis occurs when certain white blood cells known as eosinophils get into the digestive tract and cause damage. Symptoms of eosinophilic gastroenteritis usually start in adulthood and may include stomach pain, nausea, vomiting, and the inability to absorb nutrients from food. Sometimes, a blockage in the intestines occurs. In most people, symptoms occur from time to time and may go away completely with treatment. The exact cause of eosinophilic gastroenteritis is unknown, but it may be due to an abnormal response of the immune system to food allergies. Diagnosis is based on the symptoms, a clinical exam, laboratory tests, and by excluding other more common conditions. Treatment is focused on managing the symptoms and includes diet and medication.

MalaCards based summary : Eosinophilic Gastroenteritis, also known as eosinophilic gastroenterocolitis, is related to omenn syndrome and eosinophilic colitis. An important gene associated with Eosinophilic Gastroenteritis is CCL11 (C-C Motif Chemokine Ligand 11), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Fluticasone and Omeprazole have been mentioned in the context of this disorder. Affiliated tissues include small intestine, colon and bone, and related phenotypes are eosinophilia and dysphagia

Wikipedia : 73 Eosinophilic gastroenteritis (EG or EGE) is a rare and heterogeneous condition characterized by patchy... more...

Related Diseases for Eosinophilic Gastroenteritis

Diseases related to Eosinophilic Gastroenteritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 575)
# Related Disease Score Top Affiliating Genes
1 omenn syndrome 31.2 IL5 IL4 CCR6
2 eosinophilic colitis 31.0 RNASE3 PRG2
3 hypereosinophilic syndrome, idiopathic 31.0 IL5 IL3
4 ige responsiveness, atopic 31.0 RNASE3 IL5 IL4
5 peptic esophagitis 30.7 CCL26 ATP12A ALB
6 milk allergy 30.6 RNASE3 IL5 IL4
7 food allergy 30.6 RNASE3 IL5 IL4 EPX ALB
8 duodenal obstruction 30.5 ATP12A ALB
9 cow milk allergy 30.3 IL5 IL4
10 esophageal disease 30.2 CCR6 CCL26 ATP12A ALB
11 urticaria 30.2 RNASE3 PRG2 IL5 IL4 IL3
12 dyskinesia of esophagus 30.2 CCL26 ATP12A
13 hypereosinophilic syndrome 30.2 RNASE3 PRG2 IL5 IL4 IL3 EPX
14 toxocariasis 30.2 RNASE3 IL5 IL4
15 chlamydia 30.2 IL5 IL4 CSF2
16 dermatitis herpetiformis 30.2 IL5 IL4 CCL11
17 peanut allergy 30.1 IL5 IL4 CCR6
18 active peptic ulcer disease 30.1 ATP12A ALB
19 allergic bronchopulmonary aspergillosis 30.1 IL5 IL4 EPX
20 allergic rhinitis 30.1 RNASE3 IL5 IL4 EPX CSF2 CCL11
21 paralytic ileus 30.1 ATP12A ALB
22 chronic urticaria 30.1 RNASE3 IL4 IL3
23 esophageal candidiasis 30.1 CCR6 CCL26 ATP12A
24 polyposis, skin pigmentation, alopecia, and fingernail changes 30.0 ATP12A ALB
25 duodenitis 30.0 ATP12A ALB
26 mediastinitis 30.0 ATP12A ALB
27 aspiration pneumonitis 30.0 ATP12A ALB
28 intrinsic asthma 29.9 RNASE3 IL5 IL4 IL3 CSF2
29 volvulus of midgut 29.9 IL5 ATP12A ALB
30 bile reflux 29.9 ATP12A ALB
31 drug allergy 29.9 IL5 ATP12A ALB
32 eosinophilic gastritis 29.8 IL5 EPX CCL26 CCL11 ATP12A
33 churg-strauss syndrome 29.8 RNASE3 PRG2 IL5 IL3 CCL26 CCL11
34 chronic eosinophilic pneumonia 29.8 RNASE3 IL5 CSF3 CCL11
35 pollen allergy 29.7 RNASE3 PRG2 IL5 IL3 EPX
36 stomatitis 29.7 IL4 CSF3 CSF2
37 gastroenteritis 29.7 TSLP RNASE3 PRG2 IL5 IL4 IL33
38 crohn's disease 29.7 IL4 CSF2 CCR6 ALB
39 esophagitis 29.7 TSLP RNASE3 PRG2 IL5 IL4 IL33
40 visceral leishmaniasis 29.7 IL4 IL33 ALB
41 keratoconjunctivitis sicca 29.7 IL4 CCR6 ALB
42 hemolytic anemia 29.6 IL5 IL4 IL3 CSF3
43 proteasome-associated autoinflammatory syndrome 1 29.6 RNASE3 IL5 IL4 CCL11 ALB
44 bronchitis 29.6 RNASE3 IL5 IL4 CCL11 ALB
45 essential thrombocythemia 29.6 IL4 IL3 CSF3 CSF2
46 thrombocytosis 29.6 IL3 CSF3 CSF2 ALB
47 diphtheria 29.6 IL5 IL4 IL3 CSF2 ALB
48 igg4-related disease 29.5 IL4 IL33 CCR6
49 rhinitis 29.5 TSLP RNASE3 PRG2 IL5 IL4 IL33
50 egg allergy 29.5 TSLP IL5 IL4 CCR6

Graphical network of the top 20 diseases related to Eosinophilic Gastroenteritis:



Diseases related to Eosinophilic Gastroenteritis

Symptoms & Phenotypes for Eosinophilic Gastroenteritis

Human phenotypes related to Eosinophilic Gastroenteritis:

58 31 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 eosinophilia 58 31 hallmark (90%) Very frequent (99-80%) HP:0001880
2 dysphagia 58 31 frequent (33%) Frequent (79-30%) HP:0002015
3 vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002013
4 anemia 58 31 frequent (33%) Frequent (79-30%) HP:0001903
5 abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002027
6 steatorrhea 58 31 frequent (33%) Frequent (79-30%) HP:0002570
7 hypoalbuminemia 58 31 frequent (33%) Frequent (79-30%) HP:0003073
8 elevated c-reactive protein level 58 31 frequent (33%) Frequent (79-30%) HP:0011227
9 allergic rhinitis 58 31 frequent (33%) Frequent (79-30%) HP:0003193
10 ascites 58 31 occasional (7.5%) Occasional (29-5%) HP:0001541
11 asthma 58 31 occasional (7.5%) Occasional (29-5%) HP:0002099
12 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
13 hematochezia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002573
14 edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0000969
15 elevated erythrocyte sedimentation rate 58 31 occasional (7.5%) Occasional (29-5%) HP:0003565
16 atopic dermatitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001047
17 protein-losing enteropathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002243
18 malabsorption 58 Frequent (79-30%)
19 abnormality of the gastrointestinal tract 58 Frequent (79-30%)
20 diarrhea 58 Frequent (79-30%)
21 leukocytosis 58 Frequent (79-30%)
22 abnormal test result 58 Frequent (79-30%)

MGI Mouse Phenotypes related to Eosinophilic Gastroenteritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.85 CCL11 CCR6 CSF2 CSF3 EPX IL33
2 immune system MP:0005387 9.7 ALB CCL11 CCR6 CSF2 CSF3 EPX
3 respiratory system MP:0005388 9.17 CCL11 CSF2 IL33 IL4 IL5 PRG2

Drugs & Therapeutics for Eosinophilic Gastroenteritis

Drugs for Eosinophilic Gastroenteritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
2
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
3 Anti-Allergic Agents Phase 4
4 Dermatologic Agents Phase 4
5 Soy Bean Phase 4
6 Cromolyn Sodium Phase 4
7 Olive Phase 4
8
Reslizumab Approved, Investigational Phase 3 241473-69-8
9
Esomeprazole Approved, Investigational Phase 2, Phase 3 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
10
Budesonide Approved Phase 3 51333-22-3 63006 5281004
11
Benralizumab Approved, Investigational Phase 2, Phase 3 1044511-01-4
12
tannic acid Approved Phase 3 1401-55-4
13
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
14 Respiratory System Agents Phase 3
15 Anti-Asthmatic Agents Phase 3
16 Hormone Antagonists Phase 3
17 Hormones Phase 3
18 Anti-Inflammatory Agents Phase 3
19 glucocorticoids Phase 3
20 Bronchodilator Agents Phase 3
21 Immunoglobulin G Phase 3
22 Immunoglobulins, Intravenous Phase 3
23 Immunoglobulins Phase 3
24 Antibodies Phase 3
25 Antibodies, Monoclonal Phase 3
26 Immunologic Factors Phase 3
27
Omalizumab Approved, Investigational Phase 2 242138-07-4
28
Losartan Approved Phase 2 114798-26-4 3961
29
Angiotensin II Approved, Investigational Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198
30
Infliximab Approved Phase 2 170277-31-3
31
Loratadine Approved, Investigational Phase 2 79794-75-5 3957
32
Famotidine Approved Phase 2 76824-35-6 3325
33
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
34
Bethanechol Approved Phase 2 674-38-4 2370
35
mometasone furoate Approved, Investigational, Vet_approved Phase 2 83919-23-7
36
Trichostatin A Experimental Phase 2 58880-19-6
37 Anti-Arrhythmia Agents Phase 2
38 Angiotensin Receptor Antagonists Phase 2
39 Giapreza Phase 2
40 Angiotensinogen Phase 2
41 Angiotensin II Type 1 Receptor Blockers Phase 2
42 Antihypertensive Agents Phase 2
43 Vasoconstrictor Agents Phase 2
44 Antirheumatic Agents Phase 2
45 interferons Phase 1, Phase 2
46 Histamine H2 Antagonists Phase 2
47 Histamine H1 Antagonists, Non-Sedating Phase 2
48 Histamine Antagonists Phase 2
49
Histamine Phosphate Phase 2 51-74-1 65513
50 Histamine H1 Antagonists Phase 2

Interventional clinical trials:

(show top 50) (show all 157)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-blind, Placebo-controlled Study of the Use of Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed NCT02371941 Phase 4 oral cromolyn sodium;Placebo
2 COMPARISON OF TREATMENT FOR PEDIATRIC EOSINOPHILIC ESOPHAGITIS: A RANDOMIZED CLINICAL TRIAL (DIETETIC Versus TOPICAL STEROIDS) Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
3 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Completed NCT02019758 Phase 4 Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler
4 Randomized Controlled Trial Comparing Fluticasone Plus Omeprazole With Fluticasone Alone for Eosinophilic Esophagitis Recruiting NCT03781596 Phase 4 Fluticasone;Omeprazole;Placebo oral capsule
5 Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE) Recruiting NCT04149470 Phase 4 Omeprazole 20mg BID
6 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4 Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
7 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Completed NCT00728481 Phase 2, Phase 3 Esomeprazole;Budesonide
8 An Open-Label Safety and Efficacy Study of Reslizumab (CTx55700) for the Treatment of Pediatric Subjects With Eosinophilic Esophagitis Who Completed Study Res-5-0002 Completed NCT00635089 Phase 3 reslizumab
9 Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids Completed NCT02610816 Phase 2, Phase 3 Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)
10 Double-blind, Randomized, Placebo-controlled, Phase III Trial on the Efficacy and Tolerability of a 6-week Treatment With Budesonide Effervescent Tablets vs. Placebo for Induction of Clinico-pathological Remission in Adult Patients With Active Eosinophilic Esophagitis Completed NCT02434029 Phase 3 Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
11 A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE) Completed NCT02736409 Phase 3 Oral Budesonide Suspension (OBS);Placebo
12 An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Completed NCT00538434 Phase 2, Phase 3
13 Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study Completed NCT02605837 Phase 3 Oral Budesonide Suspension (OBS);Placebo
14 Effect of Swallowed Fluticasone Propionate on Eosinophilic Esophagitis; A Prospective, Randomized, Placebo-Controlled Trial Completed NCT00266578 Phase 3 Fluticasone Propionate
15 Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) Followed by Swallowed Glucocorticoid Trial Completed NCT02778867 Phase 2, Phase 3 Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)
16 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AK002 in Patients With Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) Recruiting NCT04322604 Phase 3 lirentelimab (AK002)
17 Fluticasone Propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 in Adult and Adolescent Subjects With Eosinophilic Esophagitis Recruiting NCT04281108 Phase 3 APT-1011;Placebo oral tablet
18 A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis Recruiting NCT04394351 Phase 3 Dupilumab;Matching Placebo
19 A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) Recruiting NCT03633617 Phase 3 Dupilumab;Placebo
20 A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab (AK002) in Adult and Adolescent Patients With Active Eosinophilic Esophagitis Recruiting NCT04322708 Phase 2, Phase 3 lirentelimab (AK002)
21 A Multicenter, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis Recruiting NCT04543409 Phase 3
22 A Double-Blind, Placebo-controlled Clinical Trial to Evaluate Efficacy of Benralizumab in Subjects With Eosinophilic Gastritis Active, not recruiting NCT03473977 Phase 2, Phase 3
23 Double-blind, Randomized, Placebo-controlled, Phase III Study on the Efficacy and Tolerability of a 48-week Treatment With Two Different Doses of Budesonide Effervescent Tablets vs. Placebo for Maintenance of Clinico-pathological Remission in Adult Patients With Eosinophilic Esophagitis Active, not recruiting NCT02493335 Phase 3 Budesonide 0.5mg orodispersible tablet twice daily;Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
24 A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE) Active, not recruiting NCT03245840 Phase 3 Budesonide oral suspension
25 A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Efficacy and Safety of AK002 in Patients That Were Previously Enrolled in AK002-016 or AK002-012 Studies and Have Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) Enrolling by invitation NCT04620811 Phase 3 lirentelimab
26 A Phase 3, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis Not yet recruiting NCT04753697 Phase 3 CC-93538
27 Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone Withdrawn NCT01702701 Phase 3 Montelukast;Fluticasone
28 Oral Viscous Budesonide Suspension (MB-7) in Subjects With Eosinophilic Esophagitis: A Randomized, Placebo-Controlled, Dose-Ranging Study in Children and Adolescents Completed NCT00762073 Phase 2 budesonide;placebo
29 A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab Completed NCT00123630 Phase 2 omalizumab;Placebo
30 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Completed NCT03496571 Phase 2 AK002
31 Pilot Study of Omalizumab in Eosinophilic Gastroenteritis Completed NCT00084097 Phase 2 Omalizumab
32 FLUTicasone in Eosinophilic Esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, and Maintenance Study of APT-1011 in Subjects With Eosinophilic Esophagitis Completed NCT03191864 Phase 2 APT-1011;Placebo
33 A Pilot Phase II Study of the Efficacy of Humanized Anti-IL5 Antibody (SCH55700) in Reducing Eosinophilia in Patients With Hypereosinophilic Syndrome or Eosinophilic Gastroenteritis Refractory to or Intolerant of Conventional Therapy Completed NCT00017862 Phase 2 SCH55700
34 Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis, a Randomized Clinical Trial Completed NCT00638456 Phase 2 Budesonide plus Prevacid;placebo plus Prevacid
35 A Double Blinded Randomized Placebo-controlled Trial of Intravenous QAX576 in the Treatment of Eosinophilic Esophagitis (EoE) Completed NCT01022970 Phase 2 QAX576 placebo;QAX576
36 A Double, Blind Placebo-controlled, Randomized Trial to Study Efficacy and Safety of the Viaskin Milk for Treating Milk Induced Eosinophilic Esophagitis in Children Completed NCT02579876 Phase 2 Viaskin Milk 500 mcg;Viaskin Placebo
37 Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11-40 Years of Age)With Eosinophilic Esophagitis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study With an Open Label Extension Completed NCT01642212 Phase 2 Oral Budesonide Suspension (MB-9);Placebo
38 A Randomized, Placebo-controlled, Double-blind, Single-centre Proof-of-concept Study of OC000459 in Adult Patients With Active Eosinophilic Esophagitis Completed NCT01056783 Phase 2 OC000459;Placebo
39 A Multicenter, Randomized, Double-blind, Placebo-controlled, Safety and Tolerability Phase 1/2a Study of Two Dosing Regimens of EUR-1100 for Oral Use, in Subjects With Eosinophilic Esophagitis (EoE) Completed NCT01386112 Phase 1, Phase 2 EUR-1100;placebo
40 Double-blind, Double-dummy, Randomized, Placebo-controlled, Phase IIa Study on the Efficacy and Tolerability of a 14-day Treatment With Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Patients With Eosinophilic Esophagitis Completed NCT02280616 Phase 2 low dose budesonide tablet;high dose budesonide tablet;high dose budesonide suspension;Placebo
41 A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis Completed NCT02379052 Phase 2 Dupilumab;Placebo
42 A Double Blinded, Randomized Trial of Swallowed 1760mcg Fluticasone Propionate Versus Placebo in the Treatment of Eosinophilic Esophagitis Completed NCT00426283 Phase 2 Flovent
43 A Randomized Placebo-controlled Trial of Swallowed Fluticasone in Treatment of Eosinophilic Esophagitis Completed NCT00275561 Phase 2 Fluticasone;Placebo
44 Budesonide for Eosinophilic Esophagitis: a Randomized, Placebo-controlled, Double-blind Treatment Study Completed NCT00271349 Phase 2 Budesonide
45 A Preliminary Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder Completed NCT03029091 Phase 2 Losartan Potassium
46 A Preliminary, Open-label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder. Completed NCT01808196 Phase 2 Losartan Potassium
47 A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis Completed NCT02098473 Phase 2 RPC4046;Placebo
48 Phase 2 Proof-of-Concept Study to Analyze the Efficacy of in TNF-Alpha Blockade in Adult Patients With Severe, Corticosteroid-Dependent Eosinophilic Esophagitis Completed NCT00523354 Phase 2 Infliximab
49 Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis Completed NCT00123656 Phase 2 esomeprazole;fluticasone
50 A Randomized, Double-blind, Parallel Group Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in Pediatric Subjects With Eosinophilic Esophagitis, Aged 2 to 17 Years (Study MEE103219) Completed NCT00358449 Phase 2 mepolizumab

Search NIH Clinical Center for Eosinophilic Gastroenteritis

Genetic Tests for Eosinophilic Gastroenteritis

Anatomical Context for Eosinophilic Gastroenteritis

MalaCards organs/tissues related to Eosinophilic Gastroenteritis:

40
Small Intestine, Colon, Bone, Skin, Bone Marrow, Lung, Lymph Node

Publications for Eosinophilic Gastroenteritis

Articles related to Eosinophilic Gastroenteritis:

(show top 50) (show all 880)
# Title Authors PMID Year
1
Gastrointestinal manifestations of food allergies in pediatric patients. 54 61
16207693 2005
2
Eosinophilic gastroenteritis. 54 61
15833687 2005
3
[A case of eosinophilic gastroenteritis: observation of serum IL-5 and sIL-2R levels before and after remission]. 54 61
15187490 2004
4
Allergic eosinophilic gastroenteritis in a child with Crohn's disease. 61 54
15301307 2004
5
Human intestinal mast cells produce IL-5 in vitro upon IgE receptor cross-linking and in vivo in the course of intestinal inflammatory disease. 54 61
10359103 1999
6
Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis. 61 54
8608886 1996
7
Milk-induced eczema is associated with the expansion of T cells expressing cutaneous lymphocyte antigen. 54 61
7532192 1995
8
Evidence for an abnormal profile of interleukin-4 (IL-4), IL-5, and gamma-interferon (gamma-IFN) in peripheral blood T cells from patients with allergic eosinophilic gastroenteritis. 61 54
7814459 1994
9
IgE antibodies against bovine serum albumin in a case of eosinophilic gastroenteritis. 61 54
8238812 1993
10
Interleukin-5 in eosinophilic gastroenteritis. 61 54
1380204 1992
11
A case with eosinophilic gastroenteritis exhibiting enhanced TNF-α and IL-6 responses. 61
33400188 2021
12
Small-bowel Capsule Endoscopic Features in Patients with Eosinophilic Gastroenteritis: Three Case Reports. 61
33776012 2021
13
Rare case of rapidly reaccumulating ascites. 61
33692065 2021
14
Eosinophilic gastroenteritis in an adolescent male with history of chronic bullous disease. 61
33541980 2021
15
Primary Eosinophilic Gastrointestinal Diseases Beyond Eosinophilic Esophagitis in Children. 61
32868666 2021
16
Eosinophilic gastroenteritis and graft-versus-host disease induced by transmission of Norovirus with fecal microbiota transplant. 61
32574415 2021
17
Clinical Characteristics and Treatment Outcomes of Patients with Eosinophilic Esophagitis and Eosinophilic Gastroenteritis. 61
33202408 2021
18
A Rare Case of Eosinophilic Gastroenteritis and Ampullitis Leading to Benign Papillary Stenosis. 61
33777459 2021
19
Experimental Modeling of Eosinophil-Associated Diseases. 61
33486743 2021
20
Non-IgE- or Mixed IgE/Non-IgE-Mediated Gastrointestinal Food Allergies in the First Years of Life: Old and New Tools for Diagnosis. 61
33466746 2021
21
Endoscopic findings of gastric lesions in patients with eosinophilic gastrointestinal disorders. 61
33269315 2020
22
A case report of eosinophilic gastroenteritis misdiagnosed as cholelithiasis. 61
33363834 2020
23
Eosinophilic gastroenteritis with gastric perforation-An unusual presentation. 61
33085073 2020
24
Two Cases of Eosinophilic Gastroenteritis With Rare Manifestations Revealed in Medical Checkup Findings. 61
33489532 2020
25
Eosinophilic gastroenteritis: One entity with different clinical manifestations. 61
32988642 2020
26
Eosinophilic Gastroenteritis-associated Duodenal Ulcer Successfully Treated with Crushed Budesonide. 61
32536650 2020
27
Eosinophilic colitis: an infrequent disease with difficult diagnose. 61
32958551 2020
28
Targeted Therapies for Eosinophilic Gastrointestinal Disorders. 61
32472465 2020
29
Eosinophilic gastroenteritis as a cause of non-Helicobacter pylori, non-gastrotoxic drug ulcers in children. 61
32819298 2020
30
Association of Eosinophilic Esophagitis and Human Immunodeficiency Virus. 61
32851497 2020
31
Mast Cell and Eosinophil Counts in Gastric and Duodenal Biopsy Specimens From Patients With and Without Eosinophilic Gastroenteritis. 61
32801015 2020
32
Primary eosinophilic gastroenteritis: A case series from western India. 61
32803717 2020
33
Eosinophilic gastroenteritis treated with a targeted food elimination diet. 61
32705784 2020
34
Ascites: an unusual presentation of eosinophilic gastroenteritis in a child. 61
32178592 2020
35
Solitary Duodenal Ulcer Causing Biliary Obstruction Requiring Rendezvous Procedure in a Pediatric Patient With Eosinophilic Gastroenteritis. 61
32850245 2020
36
Multiple ulcerations and perforation in the small intestine after steroid treatment in eosinophilic granulomatosis with polyangiitis: a case report and literature review. 61
32151788 2020
37
Association Between Endoscopic and Histologic Findings in a Multicenter Retrospective Cohort of Patients with Non-esophageal Eosinophilic Gastrointestinal Disorders. 61
31773359 2020
38
A Challenging Case of Recurrent Eosinophilic Peritonitis. 61
32864248 2020
39
Eosinophilic gastroenteritis: epidemiology, diagnosis, and treatment. 61
32073433 2020
40
Eosinophilic Gastroenteritis Presenting As Unexplained Chronic Abdominal Pain. 61
32685309 2020
41
Efficacy of a Short-term Six-food Elimination Diet and Reintroduction Therapy in Pediatric Eosinophilic Gastroenteritis. 61
32101833 2020
42
Eosinophilic gastroenteritis in pregnancy: A review of the literature. 61
32199294 2020
43
Abnormal thymic stromal lymphopoietin expression in the gastrointestinal mucosa of patients with eosinophilic gastroenteritis. 61
30763528 2020
44
Nationwide Multicenter Study of Eosinophilic Esophagitis in Korean Children. 61
32483544 2020
45
Eosinophilic Granulomatosis with Polyangiitis Initially Diagnosed as Eosinophilic Gastroenteritis. 61
31875634 2020
46
Gastric outlet obstruction as manifestation of eosinophilic gastroenteritis. 61
32876634 2020
47
Appearance of Gastric Polypoid Lesions in Eosinophilic Gastroenteritis. 61
31232829 2020
48
Eosinophilic ascites: an unusual manifestation of eosinophilic gastroenteritis. 61
31989248 2020
49
Eosinophilic gastroenteritis with multiple serous membrane effusion as the first sign: a case report and literature review. 61
32321384 2020
50
Myenteric networks of interstitial cells of Cajal are reduced in horses with inflammatory bowel disease. 61
31397916 2020

Variations for Eosinophilic Gastroenteritis

Expression for Eosinophilic Gastroenteritis

Search GEO for disease gene expression data for Eosinophilic Gastroenteritis.

Pathways for Eosinophilic Gastroenteritis

Pathways related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 RNASE3 PRG2 IL5 IL4 IL33 IL3
2
Show member pathways
13.71 PRG2 IL5 IL4 IL3 CSF3 CSF2
3
Show member pathways
13.55 TSLP IL5 IL4 IL33 IL3 CSF3
4
Show member pathways
13.32 IL5 IL4 IL3 CSF3 CSF2 CCR6
5
Show member pathways
13.25 IL5 IL4 IL33 IL3 CSF3 CSF2
6
Show member pathways
13.21 IL5 IL4 IL3 CSF3 CSF2 CCR6
7
Show member pathways
12.74 RNASE3 PRG2 IL5 IL4 IL3 EPX
8
Show member pathways
12.46 IL5 IL4 IL3 CSF2
9
Show member pathways
12.29 IL5 IL4 CSF3 CSF2 CCL11
10
Show member pathways
12.28 TSLP IL5 IL4 IL3 CSF3 CSF2
11 11.9 IL5 IL4 IL3 CSF3 CSF2
12
Show member pathways
11.73 IL5 IL4 IL3 CSF2
13 11.72 IL5 IL4 IL3 CSF3 CSF2
14 11.7 IL5 IL4 CSF2
15 11.62 IL5 IL4 CCL26 CCL11
16 11.6 IL5 IL4 CCR6
17 11.56 TSLP IL5 IL4 IL33 CCR6
18 11.48 IL5 IL3 CSF3 CSF2
19 11.46 IL4 CSF3 CSF2
20 11.44 IL5 IL4 IL33 CCL11
21 11.35 IL5 IL4 CSF3 CSF2 CCL11
22 11.17 TSLP IL5 IL4 IL33
23 10.7 IL5 IL4
24 10.48 IL5 IL4 IL3 CSF3 CSF2
25 10.46 PRG2 IL5 IL4 IL3 CSF3 CSF2

GO Terms for Eosinophilic Gastroenteritis

Cellular components related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 TSLP RNASE3 IL5 IL4 IL33 IL3
2 extracellular region GO:0005576 9.44 TSLP RNASE3 PRG2 IL5 IL4 IL33

Biological processes related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.12 TSLP IL5 IL4 CSF3 CCR6 CCL26
2 positive regulation of cell proliferation GO:0008284 9.8 TSLP IL5 IL4 IL3 CSF3 CSF2
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.69 IL5 IL3 CSF3
4 chemotaxis GO:0006935 9.67 RNASE3 CCR6 CCL26 CCL11
5 chemokine-mediated signaling pathway GO:0070098 9.61 CCR6 CCL26 CCL11
6 positive regulation of actin filament polymerization GO:0030838 9.58 CSF3 CCL26 CCL11
7 positive regulation of immunoglobulin production GO:0002639 9.57 IL5 IL33
8 myeloid dendritic cell differentiation GO:0043011 9.56 IL4 CSF2
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.56 TSLP IL4 IL3 CSF2
10 eosinophil chemotaxis GO:0048245 9.55 CCL26 CCL11
11 dendritic cell differentiation GO:0097028 9.54 IL4 CSF2
12 macrophage activation GO:0042116 9.52 IL4 CSF2
13 positive regulation of podosome assembly GO:0071803 9.49 IL5 CSF2
14 positive regulation of MHC class II biosynthetic process GO:0045348 9.48 IL4 IL33
15 positive regulation of interleukin-5 production GO:0032754 9.46 TSLP IL33
16 cytokine-mediated signaling pathway GO:0019221 9.43 IL5 IL4 IL3 CSF3 CSF2 CCL11
17 positive regulation of interleukin-13 production GO:0032736 9.33 TSLP IL4 IL33
18 immune response GO:0006955 9.28 PRG2 IL5 IL4 IL3 CSF3 CSF2

Molecular functions related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.35 IL5 IL4 IL3 CSF3 CSF2
2 cytokine activity GO:0005125 9.28 TSLP IL5 IL4 IL33 IL3 CSF3
3 CCR3 chemokine receptor binding GO:0031728 9.16 CCL26 CCL11

Sources for Eosinophilic Gastroenteritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....